Recursion And Citeline Deepen AI Trial Data Tie For RXRX Investors

Recursion Pharmaceuticals expanded its collaboration with Citeline to integrate real world data into its AI enabled ClinTech Platform. The partnership is aimed at refining clinical trial design and ...
Seeking Alpha

Recursion Pharmaceuticals: More Hype Than Substance Amid Signs Of Progress

Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. The company raised over $500 million in its IPO, making it the sixth-largest ...
C&EN

Recursion to buy AI rival Exscientia

The business of using artificial intelligence to find new drugs is starting to consolidate. The AI-powered drug discovery firm Recursion Pharmaceuticals will buy rival Exscientia in an all-stock deal ...
Nasdaq

Where Will Recursion Pharmaceuticals Be in 3 Years?

Recursion Pharmaceuticals (NASDAQ: RXRX) is a biotech that's riding a hype wave unlike any other. By staking its fame and investors' cash on its artificial intelligence (AI) platform for drug ...
GEN

Drugs, Dollars, and Data: Recursion Eyes Cost Savings from AI Drug Discovery

Announcing an artificial intelligence (AI) drug discovery partnership with Nvidia earlier this month, Recursion co-founder and CEO Chris Gibson, PhD, spoke as much about dollars as he did about drugs ...